LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Werfen and Instrumentation Laboratory Acquire Accriva Diagnostics

By LabMedica International staff writers
Posted on 26 Jan 2017
Print article
Werfen and its subsidiary Instrumentation Laboratory (IL) have acquired Accriva Diagnostics, which provides in vitro diagnostic (IVD) blood testing at the Point-of-Care (POC).

Werfen develops, manufactures and distributes IVD testing solutions, systems, reagents and software to hospitals and clinical laboratories around the world. An integral part of Werfen, IL develops and manufactures hemostasis, critical care, and patient blood management (PBM) products. The acquisition of Accriva, whose product portfolio includes coagulation, platelet aggregation, CO-Oximetry, and incision devices, will allow IL to further enhance its position in hospital-based POC hemostasis testing, POC critical care testing, and the hemostasis laboratory segment.

"Over the course of our 50-year history, we have demonstrated our strong commitment to expanding our IVD business through organic growth, complemented with highly strategic acquisitions," said Carlos Pascual, CEO at Werfen. "Like our recent acquisition of CA Casyso AG and its Tem subsidiaries, the acquisition of Accriva is exemplary of this commitment, as well as the confidence we have in our future together."

"By acquiring Accriva, we are expanding our product offering, expertise, and know-how in POC testing, particularly for hemostasis," said Ramon Benet, CEO at IL. "The addition of Accriva products to our strong critical care, hemostasis and PBM portfolios creates an even more comprehensive and integrated testing solution for hospital acute care settings and laboratories, further impacting positive clinical outcomes and reducing healthcare costs."

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more